New York State Teachers Retirement System Buys 5,689 Shares of TransMedics Group, Inc. $TMDX

New York State Teachers Retirement System boosted its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 25.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 27,638 shares of the company’s stock after purchasing an additional 5,689 shares during the quarter. New York State Teachers Retirement System owned approximately 0.08% of TransMedics Group worth $3,704,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Atria Wealth Solutions Inc. bought a new position in TransMedics Group in the 2nd quarter worth about $316,000. Envestnet Portfolio Solutions Inc. purchased a new stake in shares of TransMedics Group in the 2nd quarter valued at about $559,000. Total Clarity Wealth Management Inc. purchased a new stake in shares of TransMedics Group in the 2nd quarter valued at about $386,000. Yousif Capital Management LLC raised its holdings in shares of TransMedics Group by 2.2% in the 2nd quarter. Yousif Capital Management LLC now owns 12,908 shares of the company’s stock valued at $1,730,000 after acquiring an additional 277 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in shares of TransMedics Group in the 2nd quarter valued at about $286,000. Institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on TMDX shares. Zacks Research cut TransMedics Group from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Monday, August 25th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $142.00 price target on shares of TransMedics Group in a report on Tuesday, October 14th. Stifel Nicolaus started coverage on TransMedics Group in a report on Thursday, September 4th. They issued a “hold” rating and a $115.00 price target on the stock. Finally, Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a report on Saturday. Seven equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $127.18.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX opened at $119.90 on Tuesday. The stock has a market cap of $4.09 billion, a price-to-earnings ratio of 62.12 and a beta of 2.08. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $145.50. The stock’s 50-day moving average is $116.37 and its 200 day moving average is $114.31.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.44. The company had revenue of $157.37 million for the quarter, compared to analysts’ expectations of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.TransMedics Group’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same period last year, the firm posted $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.